Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00187174
Status:
COMPLETED
Last Update Posted:
2015-03-04
First Post:
2005-09-13
Brief Title:
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
Sponsor:
St Jude Childrens Research Hospital
Organization:
St Jude Childrens Research Hospital
Study Overview
Official Title:
Phase I Trial of RAD001C Everolimus in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy or with no known effective therapy will be treated Experiments in the laboratory have shown the experimental drug RAD001C RAD001 Everolimus can prevent cells from multiplying RAD001 is now being tested in diseases such as cancer in which excessive cell multiplication needs to be stopped The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies It is experimental and therefore available in clinical trials
Detailed Description:
Although a Phase II portion of this study was planned it was never initiated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None